In 2004 biotech firm Amgen began trials of a Parkinson's drug called glial cell line-derived neurotrophic factor, or GDNF.

FORBES: Magazine Article

In 2004 biotech firm Amgen (nasdaq: AMGN - news - people ) began trials of a Parkinson's drug called glial cell line-derived neurotrophic factor, or GDNF.

FORBES: On The Cover/Top Stories